International Department

CT011 is an autologous GPC3 CAR T-cell product candidate for the treatment of hepatocellular carcinoma (HCC). CT011 received IND clearance from the NMPA in 2019 for the treatment of patients with GPC3-positive solid tumor which was China’s first IND clearance for CAR T-cell therapy against solid ...Read more »

A Russian university professor in his late seventies suffers from advanced multiple myeloma. After undergoing multiple treatments and two recurrences of autologous transplantation, he learned about the cutting-edge anti-cancer therapy CAR-T in China, so he came to China to receive CAR-T cell ther...Read more »

On July 20th,the New Drug Application (NDA) of pCAR-19B independently developed by Precision Biology was officially accepted by China National Medical Products Administration (NMPA).This product is the first CAR-T product for childhood leukemia in China, which is used to treat patients aged 3-21 ...Read more »

satricabtagene autoleucel（Satri-cel,CT041) is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be first-in-class globally. Satri-cel targets Claudin18.2 positive solid tumors with a primary focus on gastric cancer/gastroesophageal junction canc...Read more »

On September 6, 2021,JW Therapeutics announced that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (relma-cel) ...Read more »

Equecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (R/RMM). On June 30,2023,China’s National Medical Products Admi...Read more »

On October 11, 2024,China’s National Medical Product Administration (NMPA) has approved  Investigational New Drug（IND）application for Inaticabtagene Autoleucel (CNCT19 Injection), a CD19-targeted autologous chimeric antigen receptor (CAR)-T cell therapy, to treat  Immune thrombocytopenia ...Read more »

On March 1st, 2024, China National Medical Products Administration (NMPA) approved the launch of CAR-T cell product Zevorcabtagene AutoLeucel (Zevor-cel, CT053) for the treatment of adult patients with relapsed or refractory multiple myeloma who had progressed after at least 3 lines of treatment(...Read more »